Skip to main content
SpringerLink
Log in

Antipsychotika

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

  • 5234 Accesses

Zusammenfassung

Antipsychotika sind eine chemisch heterogene Gruppe von Pharmaka mit antipsychotischem Wirksamkeitsschwerpunkt und unterschiedlichem NW-Profil. Der häufig synonym verwendete Begriff »Neuroleptikum« wird international weitgehend durch den Begriff Antipsychotikum ersetzt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Andreasen NC, Liu D, Ziebell S et al (2013) Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013 170(6):609–615

    Article  PubMed  Google Scholar 

  • Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25(5):383–399

    Article  PubMed  Google Scholar 

  • Choi KH, Wykes T, Kurtz MM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry 203:172–178

    Article  PubMed Central  PubMed  Google Scholar 

  • Declercq T, Petrovic M, Azermai M et al (2013) Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 3:CD007726

    Google Scholar 

  • DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde) (Hrsg) (2006) Behandlungsleitlinie Schizophrenie. Reihe: S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1. Springer, Berlin Heidelberg New York

    Google Scholar 

  • DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (2012) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression; Langfassung Version 1.3. Januar, basierend auf der Fassung von November 2009. AWMF- Register-Nr. nvl-005

    Google Scholar 

  • Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23:1023–1033

    Article  CAS  PubMed  Google Scholar 

  • Fan Z, Wu Y, Shen J et al (2013) Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 47:1549–1556

    Article  PubMed  Google Scholar 

  • Farahani A, Correll CU (2012) Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 73(4):486–496

    Article  CAS  PubMed  Google Scholar 

  • Gallego JA, Bonetti J, Zhang J et al (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18–28

    Article  PubMed Central  PubMed  Google Scholar 

  • Gareri P, De Fazio P, Manfredi VG et al (2014) Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 34(1):109–123

    Article  CAS  PubMed  Google Scholar 

  • Harrow M, Jobe TH (2013) Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 39(5):962–965

    Article  PubMed Central  PubMed  Google Scholar 

  • Hsieh PH, Hsiao FY, Gau SS, Gau CS (2013) Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study. J Clin Psychopharmacol 33(3):299–305

    Article  CAS  Google Scholar 

  • Jarskog LF, Hamer RM, Catellier DJ (2013) Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 170(9):1032–1040

    Article  PubMed  Google Scholar 

  • Jauhar S, McKenna PJ, Radua J et al (2014) Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204:20–29

    Article  CAS  PubMed  Google Scholar 

  • Kales HC, Kim HM, Zivin K et al (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry169(1): 71–79

    Google Scholar 

  • Kane JM, Kishimoto T, Correll CU (2013) Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12:216–226

    Article  PubMed Central  PubMed  Google Scholar 

  • Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1):11–24

    Article  PubMed Central  PubMed  Google Scholar 

  • Khan A, Faucett J, Morrison S et al (2013) Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/ hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 70(10):1091–1099

    Article  PubMed  Google Scholar 

  • Kishimoto T, Agarwal V, Kishi T et al (2013a) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 18(1):53–66

    Article  CAS  Google Scholar 

  • Kishimoto T, Nitta M, Borenstein M et al (2013b) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74(10):957–965

    Article  Google Scholar 

  • Kishimoto T, Robenzadeh A, Leucht C et al (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192–213

    Article  PubMed  Google Scholar 

  • Klosterkötter J (2013) Prävention psychotischer Störungen. Nervenarzt 84(11):1299–1309

    Article  PubMed  Google Scholar 

  • Kristensen D, Hageman I, Bauer J et al (2013) Antipsychotic polypharmacy in a treatment- refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. JECT 29:271–276

    Article  PubMed  Google Scholar 

  • Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127(1–3):83–92

    Article  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962

    Article  CAS  Google Scholar 

  • Leucht S, Samara M, Heres S et al (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2): 314-326

    Google Scholar 

  • Lopez OL, Becker JT, Chang YF et al (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 170(9): 1051-1058

    Google Scholar 

  • Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35(7):1520-1530

    Google Scholar 

  • Mahmood S, Booker I, Huang J, Coleman CI (2013) Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33: 90-94

    Google Scholar 

  • Nielsen J, Damkier P, Lublin H et al (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411–422

    Article  CAS  PubMed  Google Scholar 

  • Nielsen J, Correll CU, Manu P et al (2013) Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 74:603–613

    Article  CAS  PubMed  Google Scholar 

  • Osser DN, Roudsari MJ, Manschreck T (2013) The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 21:18–40

    Article  PubMed  Google Scholar 

  • Porcelli S, Balzarro B, Serretti A (2012) Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22(3):165–182

    Article  CAS  PubMed  Google Scholar 

  • Schennach R, Riesbeck M, Mayr A et al (2013) Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr Scand 127:474–481

    Article  CAS  PubMed  Google Scholar 

  • Sommer IE, Begemann MJ, Temmerman A et al (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38:1003–1011

    Article  PubMed Central  PubMed  Google Scholar 

  • Steinert T, Baier H, Fröscher W, Jandl M (2011) Epileptische Anfälle unter der Behandlung mit Antidepressiva und Neuroleptika. Fortschr Neurol Psychiatr 79(3):138–143

    Article  CAS  PubMed  Google Scholar 

  • Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 125:15–24

    Article  CAS  PubMed  Google Scholar 

  • Tiihonen J, Suokas JT, Suvisaari JM et al (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69:476–483

    Article  CAS  PubMed  Google Scholar 

  • Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de Pointes. Dtsch Arztebl Int 108(41):687–693

    PubMed Central  PubMed  Google Scholar 

  • Wolter DK (2009) Risiken von Antipsychotika im Alter, speziell bei Demenzen. Z Geronto-psychol -psychiatrie 22(1): 17–56

    Google Scholar 

  • Wu CS, Wang SC, Gau SS et al (2013) Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 73(5):414–421

    Article  CAS  PubMed  Google Scholar 

  • Wunderink L, Nieboer RM, Wiersma D et al (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70(9):913–920

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mainz

    O. Benkert

Authors
  1. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Benkert, O. (2015). Antipsychotika. In: Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54769-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54769-0_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54768-3

  • Online ISBN: 978-3-642-54769-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation